Skip to main content
spacbrain

POINT Biopharma Global

Closed (deSPAC)

Health Care · radiopharmaceutical therapy development

What it is
Biopharma Global, Inc
What it’s doing now
Merging with Therapeutics Acquisition Corp. (RACA) — closed (despac).
What you should know
Data is still being assembled for this company — what is shown below is everything we have verified so far.

The business, per its filings

SEC primary

Biopharma Global, Inc. POINT Biopharma Global, Inc. is a globally focused radiopharmaceutical company building a platform for the clinical development and commercialization of radioligands that fight cancer. POINT aims to transform precision oncology by combining a portfolio of targeted radioligand assets, a seasoned management team, an industry-leading pipeline, in-house manufacturing capabilities, and secured supply for medical isotopes including actinium-225 and lutetium-177. POINT’s active clinical trials include FRONTIER, a phase 1 trial for PNT2004, a pan-cancer program targeting fibroblast activation protein-α (FAP-α), and SPLASH, the phase 3 trial for PNT2002 for people with metastatic castration resistant prostate cancer (mCRPC) after second-line hormonal treatment. Learn more about POINT Biopharma Global, Inc. at pointbiopharma.com .

Source: S-4/A, accession 0001104659-21-059406

What the company says about itself

Web research — not audited
What our web check found

[WEB-INTEL 2026-08-26] 2 finding(s) · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Lilly will commence a tender offer to acquire all outstanding shares of POINT for a purchase price of $12.50 per share in cash (an aggregate of approximately $1.4 billion) payable at closing." [https://www.prnewswire.com/news-releases/lilly-to-acquire-point-biopharma-to-expand-oncology-capabilities-into-next-generation-radioligand-therapies-301945243.html] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "The transaction is not subject to any financing condition and is expected to close near the end of 2023" [https://www.prnewswire.com/news-releases/lilly-to-acquire-point-biopharma-to-expand-oncology-capabilities-into-next-generation-radioligand-therapies-301945243.html] [WEB-INTEL 2026-08-26] 2 finding(s) · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Lilly will commence a tender offer to acquire all outstanding shares of POINT for a purchase price of $12.50 per share in cash (an aggregate of approximately $1.4 billion) payable at closing." [https://www.prnewswire.com/news-releases/lilly-to-acquire-point-biopharma-to-expand-oncology-capabilities-into-next-generation-radioligand-therapies-301945243.html] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "The transaction is not subject to any financing condition and is expected to close near the end of 2023" [https://www.prnewswire.com/news-releases/lilly-to-acquire-point-biopharma-to-expand-oncology-capabilities-into-next-generation-radioligand-therapies-301945243.html] [WEB-INTEL 2026-08-28] 2 finding(s) · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "purchase price of $12.50 per share in cash (an aggregate of approximately $1.4 billion)" [https://www.prnewswire.com/news-releases/lilly-to-acquire-point-biopharma-to-expand-oncology-capabilities-into-next-generation-radioligand-therapies-301945243.html] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "expected to close near the end of 2023" [https://www.prnewswire.com/news-releases/lilly-to-acquire-point-biopharma-to-expand-oncology-capabilities-into-next-generation-radioligand-therapies-301945243.html] [WEB-INTEL 2026-08-28] 2 finding(s) · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Lilly will commence a tender offer to acquire all outstanding shares of POINT for a purchase price of $12.50 per share in cash (an aggregate of approximately $1.4 billion) payable at closing." [https://www.prnewswire.com/news-releases/lilly-to-acquire-point-biopharma-to-expand-oncology-capabilities-into-next-generation-radioligand-therapies-301945243.html] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "The transaction is not subject to any financing condition and is expected to close near the end of 2023, subject to customary closing conditions, including the tender of a majority of the outstanding shares of POINT's common stock, and lice" [https://www.prnewswire.com/news-releases/lilly-to-acquire-point-biopharma-to-expand-oncology-capabilities-into-next-generation-radioligand-therapies-301945243.html] [WEB-INTEL 2026-08-28] 2 finding(s) · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Lilly will commence a tender offer to acquire all outstanding shares of POINT for a purchase price of $12.50 per share in cash (an aggregate of approximately $1.4 billion) payable at closing." [https://www.prnewswire.com/news-releases/lilly-to-acquire-point-biopharma-to-expand-oncology-capabilities-into-next-generation-radioligand-therapies-301945243.html] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "The transaction is not subject to any financing condition and is expected to close near the end of 2023" [https://www.prnewswire.com/news-releases/lilly-to-acquire-point-biopharma-to-expand-oncology-capabilities-into-next-generation-radioligand-therapies-301945243.html] [WEB-INTEL 2026-08-29] 1 finding(s) · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Lilly will commence a tender offer to acquire all outstanding shares of POINT for a purchase price of $12.50 per share in cash (an aggregate of approximately $1.4 billion) payable at closing." [https://www.prnewswire.com/news-releases/lilly-to-acquire-point-biopharma-to-expand-oncology-capabilities-into-next-generation-radioligand-therapies-301945243.html] [WEB-INTEL 2026-08-29] 4 finding(s) · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "The business combination is expected to be completed by mid-year 2021." [https://www.globenewswire.com/news-release/2021/03/15/2192554/0/en/next-generation-radiopharmaceuticals-company-point-biopharma-to-list-on-nasdaq-through-merger-with-research-alliance-corp-i.html] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Upon closing, expected to be mid-year 2021, the combined company will be renamed POINT Biopharma Global Inc." [https://bassberry.com/experience/lead-counsel-to-point-biopharma-inc-in-its-spac-business-combination-with-research-alliance-corp-i/] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Lilly will commence a tender offer to acquire all outstanding shares of POINT for a purchase price of $12.50 per share in cash (an aggregate of approximately $1.4 billion) payable at closing." [https://www.prnewswire.com/news-releases/lilly-to-acquire-point-biopharma-to-expand-oncology-capabilities-into-next-generation-radioligand-therapies-301945243.html] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "The transaction ... is expected to close near the end of 2023" [https://www.prnewswire.com/news-releases/lilly-to-acquire-point-biopharma-to-expand-oncology-capabilities-into-next-generation-radioligand-therapies-301945243.html] [WEB-INTEL 2026-09-06] 8 finding(s) · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Lilly will commence a tender offer to acquire all outstanding shares of POINT for a purchase price of $12.50 per share in cash (an aggregate of approximately $1.4 billion) payable at closing." [https://www.prnewswire.com/news-releases/lilly-to-acquire-point-biopharma-to-expand-oncology-capabilities-into-next-generation-radioligand-therapies-301945243.html] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "The transaction is not subject to any financing condition and is expected to close near the end of 2023, subject to customary closing conditions, including the tender of a majority of the outstanding shares of POINT's common stock, and lice" [https://www.prnewswire.com/news-releases/lilly-to-acquire-point-biopharma-to-expand-oncology-capabilities-into-next-generation-radioligand-therapies-301945243.html] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "POINT Biopharma has raised $650M in total disclosed funding. The most recent round on record is a IPO round of $300M in July 2021." [https://startupfundraising.com/companies/point-biopharma] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Point Biopharma Global has raised $310M." [https://pitchbook.com/profiles/company/437830-12] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "POINT Biopharma has raised a total funding of $20M over 1 round." [https://tracxn.com/d/companies/point-biopharma/__BjW0tZxf1giAwoDOCDl5IqbFQXf5dtHdZa2_5hsD9fQ] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "The business combination is expected to be completed by mid-year 2021." [https://www.globenewswire.com/news-release/2021/03/15/2192554/0/en/next-generation-radiopharmaceuticals-company-point-biopharma-to-list-on-nasdaq-through-merger-with-research-alliance-corp-i.html] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Upon closing, expected to be mid-year 2021, the combined company will be renamed POINT Biopharma Global Inc. and is expected to be listed on the Nasdaq Capital ..." [https://bassberry.com/experience/lead-counsel-to-point-biopharma-inc-in-its-spac-business-combination-with-research-alliance-corp-i/] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "POINT Biopharma was acquired by Eli Lilly in October 2023." [https://www.racap.com/portfolio/point-biopharma]

Source: company web presence · marketing claims are reported as claims, never merged into the filed figures above.

The deal it’s entering

POINT Biopharma Global is merging with Therapeutics Acquisition Corp. (RACA) currently marked Closed (deSPAC).

Headline equity value—
PIPE≈ $165M · unsourced

Structure per SEC accession(s) 0001104659-21-039931, 0001104659-21-059406. How to read these numbers: headline vs effective valuation · what a definitive agreement commits

What exactly is being valued, and at what

Common questions

Is POINT Biopharma Global going public?

POINT Biopharma Global has an approved merger with the SPAC Therapeutics Acquisition Corp. (RACA). Deal status: Closed (deSPAC).

Does POINT Biopharma Global have revenue?

The filings we've parsed don't state a usable revenue figure yet; this profile is updated as new documents land.

Educational content, not investment advice.

Other health care deals